ONCO — Onconetix Income Statement
0.000.00%
Last trade - 00:00- $3.59m
- $2.91m
- $2.52m
- 23
- 39
- 16
- 14
Annual income statement for Onconetix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.058 | 2.52 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | -1.13 | 1.06 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.62 | 3.42 | 13.5 | 36.6 | 59 |
| Operating Profit | -1.62 | -3.42 | -13.5 | -36.5 | -56.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.6 | -3.42 | -13.4 | -37.4 | -59.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.6 | -3.42 | -13.4 | -37.4 | -58.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.6 | -3.42 | -13.4 | -37.4 | -58.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.16 | -4.04 | -13.5 | -37.4 | -58.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -665 | -1,245 | -3,745 | -5,021 | -895 |
| Dividends per Share |